Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model  by McMillan, Laura E. et al.
PL
a
b
c
a
A
R
R
A
K
A
G
G
G
P
S
S
T
U
U
A
t
(
p
c
c
t
[
t
d
i
a
a
p
m
R
h
0
dNeuroscience Letters 502 (2011) 201– 208
Contents lists available at ScienceDirect
Neuroscience  Letters
jou rn al h om epage: www.elsev ier .com/ locate /neule t
roﬁles  of  SUMO  and  ubiquitin  conjugation  in  an  Alzheimer’s  disease  model
aura  E.  McMillana, Jon  T.  Brownb, Jeremy  M.  Henleya,∗, Helena  Cimarosti a,c,∗∗
MRC Centre for Synaptic Plasticity, School of Biochemistry, Medical Sciences Building, University of Bristol, University Walk, Bristol BS8 1TD, UK
MRC  Centre for Synaptic Plasticity, School of Physiology and Pharmacology, Medical Sciences Building, University of Bristol, University Walk, Bristol BS8 1TD, UK
School of Pharmacy, Hopkins Building, University of Reading, Whiteknights, Reading RG6 6UB, UK
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 11 April 2011
eceived  in revised form 14 July 2011
ccepted 26 July 2011
eywords:
lzheimer’s disease
lutamate  receptors
luA1
luK2/3
osttranslational modiﬁcation
ENP-1
a  b  s  t  r  a  c  t
Alzheimer’s  disease  (AD)  is a major  cause  of  disability  in  the  elderly.  The  formation  of senile  plaques  and
neuroﬁbrillary  tangles  are  the  main  hallmarks  of  the disorder,  whereas  synaptic  loss  best  correlates  to the
progressive  cognitive  decline.  Interestingly,  some  of  the  proteins  involved  in  these  pathophysiological
processes  have  been  reported  to  be subject  to  posttranslational  modiﬁcation  by  ubiquitin and/or  the
small  ubiquitin-like  modiﬁer  (SUMO).  Here  we  investigated  global  changes  in protein  SUMOylation  and
ubiquitination  in  vivo  in a model  of  AD.  We  used  Tg2576  transgenic  mice,  which  overexpress  a  mutated
human  amyloid  precursor  protein  (APP)  gene  implicated  in  familial  AD.  As  expected,  APP protein  levels
were  dramatically  increased  in the  hippocampus,  cortex  and  cerebellum  of  Tg2576  mice.  A  signiﬁcant
increase  in  the  global  level  of ubiquitinated  proteins  was  observed  in  the  hippocampus  of Tg2576  mice.
Signiﬁcant  or  close  to signiﬁcant  changes  in  individual  bands  of  SUMO-1  or SUMO-2/3  conjugation  were
apparent  in all brain  regions  investigated,  although  global  levels  were  unaltered  between  wild-type  andUMO
g2576  mice
BC9
biquitin
transgenic  mice.  Levels  of  SUMO-speciﬁc  conjugating  and  deconjugating  enzymes,  UBC9  and  SENP-1
were  also unaltered  in  any  of  the  brain  regions  analysed.  Surprisingly,  given  the  well-documented  loss  of
synaptic  function,  total  levels  of  the excitatory  AMPA  and  kainate  receptors  were  unaffected  in the  Tg2576
mice.  These  results  suggest  that  alterations  in  SUMO  substrate  conjugation  may  occur  and  that  global
posttranslational  modiﬁcations  by ubiquitin  may  play  an important  role  in  the  mechanisms  underlying
AD.lzheimer’s disease (AD) is the most common neurodegenera-
ive disorder and cause of dementia among the aging population
http://www.alz.co.uk/research/worldreport/). It has a complex
athophysiology, which, although not completely understood, is
haracterised by beta-amyloid (A) senile plaques originating from
leavage of the amyloid precursor protein (APP) and neuroﬁbrillary
angles formed from hyperphosphorylated microtubule protein tau
28]. Synaptic loss is another characteristic feature of the condi-
ion and probably the best correlate of the cognitive decline that
evelops progressively in AD patients [27]. Several lines of evidence
ndicate that excitatory synapses are lost due to a decrease in AMPA
nd NMDA receptors at the cell surface caused by extracellular
ccumulation of A [24].
Ubiquitination and SUMOylation are key protein modiﬁcation
athways that involve a sequence of analogous but distinct enzy-
atic steps to covalently conjugate either ubiquitin or SUMO (small
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ubiquitin-like modiﬁer) to substrate proteins. Generally, ubiqui-
tinated proteins are targeted to the proteasome for degradation
(reviewed in [25]), whereas proteins tagged by one of the validated
SUMO paralogues (SUMO-1 to -3, the difference between SUMO-2
and -3 being only three amino acids) can undergo changes in local-
isation, activity and/or stability (reviewed in [29]). Both ubiquitin
and SUMO conjugation pathways play critical roles in diverse phys-
iological and pathophysiological processes [22,30,32]. High levels
of ubiquitinated proteins have been observed in all major neu-
rodegenerative disorders including AD [18]. Recently, alterations in
global levels of SUMOylated proteins have been reported in a num-
ber of these diseases (for review see [4]) and several AD-associated
proteins, including APP and tau, have been shown to be SUMOy-
lated [9,11,33].
Tg2576 transgenic mice, which overexpress a mutated APP
gene containing the Swedish familial AD mutation, are a widely
recognised model of AD [14]. These mice exhibit elevated A
that lead to plaque pathology and behavioral deﬁcits analogous
to that of AD patients (for review see [14]). Previous in vivo and
Open access under CC BY license.in vitro studies using Tg2576 mice have shown impairment of the
ubiquitin–proteasome system as well as reduction in the surface
expression of AMPA receptors [2,3,23]. Here we investigated poten-
tial changes in protein SUMOylation and ubiquitination patterns,
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Fig. 1. APP protein levels are increased in Tg2576 transgenic mice in all brain regions analysed. Nine-month Tg2576 transgenic and age-matched wild-type mice were
decapitated, their brains removed and dissected into hippocampus, cortex and cerebellum. Regions from both hemispheres were pooled together and tissue lysates prepared
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ior  Western blotting. Representative immunoblots showing APP immunoreactivit
erebellar (C) regions of wild-type and Tg2576 mice. The quantiﬁed APP data show
resented as percentage of wild-type ± SEM. *Signiﬁcant difference compared to w
UMO-speciﬁc conjugating (UBC9) and deconjugating (SENP-1)
nzymes, and levels of AMPA and kainate (KA) receptor subunits
n Tg2576 mice. As expected, our results show a dramatic increase
f APP protein levels in the hippocampus, cortex and cerebellum,
hough surprisingly, given the reported loss of synaptic function,
evels of the excitatory AMPA and KA receptors were unaffected. A
obust increase in total ubiquitinated proteins was seen in the hip-
ocampus of Tg2576 mice, but not in the cortex or cerebellum. A
ecrease in SUMO-2/3 conjugation of high molecular weight pro-
eins was evident in the cortex of transgenic mice, and although
hanges in the modiﬁcation of multiple SUMO-1 and SUMO-2/3
onjugates were apparent in all brain regions, no other signiﬁcant
hanges in conjugation or in levels of SUMO conjugation machinery
ere observed between transgenic and control mice.
Animal care and experimental procedures were conducted in
ccordance with UK Home Ofﬁce legislation and experimental pro-
ocols approved by the British National Committee for Ethics in
nimal Research.
Hippocampal, cortical and cerebellar regions were prepared
rom 9-month male Tg2576 mice and wild-type age-matched
ontrols processed in parallel. Brains were immediately removed
ollowing cervical dislocation and dissected in ice cold Hank’s bal-
nced salt solution (HBSS, pH 7.2) containing (in mM):  1.26 CaCl2,
.36 KCl, 136.89 NaCl, 36.08 glucose, 0.44 KH2PO4, 0.34 Na2HPO4,
.49 MgCl2, 0.44 MgSO4, 25 HEPES and 4 NaHCO3. For each of
he regions, both hemispheres were pooled together in ice-cold
ysis buffer containing: 50 mM Tris–HCl (pH 7.4), 150 mM NaCl,
 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% mammalian protease
nhibitor (Roche) and 20 mM NEM (Sigma–Aldrich). For the tis-
ue homogenisation protocol, equivalent amounts of tissue were
ysed in equivalent buffer volumes, samples were sonicated for
0 s at 4 ◦C and total protein concentrations were determined as
reviously reported [8].
An appropriate volume of loading buffer consisting of 125 mMris–HCl (pH 6.8), 20% glycerol, 4% SDS, 0.01% bromophenol blue
nd 5% -mercaptoethanol was added to the samples, which were
hen boiled for 5 min  at 95 ◦C. Equal amounts of protein loaded
ig. 2. Pattern of global protein SUMOylation and ubiquitination in Tg2576 transgenic 
left  panel), SUMO-2/3 (center panel) and ubiquitin (right panel) conjugated proteins an
erebellum (C) of wild-type and Tg2576 mice. The experimental protocol was as described
or  each region showing quantiﬁed data from at least six animals of each group are prese
ands  that were individually quantiﬁed and the presence of an * denotes a signiﬁcant diffe
n  Table 1 and Supplementary Fig. S1. the respective -actin loading controls in the hippocampal (A), cortical (B) and
 each region was obtained from at least six animals of each group. The results are
e, p < 0.05.
at 10–50 g protein/lane were resolved by SDS-PAGE (8–15%) and
immunoblotting was performed as formerly described [8].  The pri-
mary antibodies used were: rabbit polyclonal anti-APP (Sigma;
1:4000), mouse monoclonal anti-ubiquitin (Santa Cruz; 1:500),
rabbit polyclonal anti-SUMO-1 (1:4000) kindly provided by Dr.
M. Dasso, rabbit polyclonal anti-SUMO-2/3 (Zymed; 1:250), rab-
bit polyclonal anti-SENP-1 (Imgenex; 1:1000), rabbit polyclonal
anti-UBC9 (Santa Cruz; 1:250), mouse monoclonal anti-GluA1 (Mil-
lipore; 1:2000), rabbit monoclonal anti-GluK2/3 (Upstate; 1:1000)
and mouse monoclonal anti--actin (Sigma; 1:10,000). For each
region (hippocampus, cortex and cerebellum), samples from at
least six Tg2576 mice were compared to an equal number of wild-
type age-matched controls on the same Western blot to avoid
differences in signal intensity. The same blots were then re-probed
with anti--actin antibody as an internal control to ensure equal
protein loading in all lanes. Densitometry was  performed on blots
for each brain region and analysed using Image J (NIH). For SUMO
and ubiquitin conjugate multiple bands the entire lane with a max-
imum range of 15–250 kDa as well as individual prominent bands
were analysed. Band intensity values for the investigated proteins
were normalised against the internal loading control values and
the mean normalised value obtained for the wild-type group was
designated as 100%.
Results are expressed as mean ± SEM of the indicated number
of animals. Student’s t-test was applied to the means to determine
differences between experimental groups. p Values < 0.05 were
considered statistically signiﬁcant.
Tg2576 mice show increased APP protein levels in all brain
regions analysed: To conﬁrm that Tg2576 mice, which overexpress
the Swedish double mutation (K670N, M671L) of the human APP
gene, produce increased levels of APP protein compared to their
age-matched controls, we  performed Western blots in samples
from brain regions of transgenic and wild-type mice. As expected,
the transgenic mice express increased APP protein levels by at least
3-fold in the hippocampus (Fig. 1A), cortex (Fig. 1B) and cerebel-
lum (Fig. 1C). The increase in APP protein levels in the transgenic
mice provides increased substrate for -secretase, an enzyme that
and age-matched wild-type mice. Representative immunoblots of global SUMO-1
d their respective -actin loading controls in the hippocampus (A), cortex (B) and
 in Fig. 1. Cumulative global levels of SUMO-1-, SUMO-2/3- and ubiquitin-conjugates
nted as percentage of wild-type ± SEM. In addition, the arrows indicate prominent
rence compared to wild-type, p < 0.05. The data from individual bands are presented
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Table  1
Comparison of individual SUMOylated or ubiquitinated protein bands in Tg2576 transgenic and age-matched wild-type mice. Discrete prominent bands were identiﬁed
on  the blots used for the cumulative data presented in Fig. 2 and individually compared. Arrows in the representative blots in Fig. 2 indicate the quantiﬁed band and the
approximate MW values are given in the table. Data quantiﬁed from at least six animals of each group are presented as percentage of wild-type. p-Value indicates signiﬁcance,
and  * on the respective blots in Fig. 2 denotes a signiﬁcant difference compared to wild-type, p < 0.05.
SUMO-1 SUMO-2/3 Ubiquitin
MW (kDa) Tg (mean wt%) p Value MW (kDa) Tg (mean wt%) p Value MW (kDa) Tg (mean wt%) p Value
Hippocampus
Full lane 119 0.18 Full lane 137 0.18 Full lane 191 <0.01
∼130  130 0.45 ∼150 94 0.86 ∼100 251 <0.01
∼98  127 0.41 ∼130 90 0.74 ∼90 184 <0.01
∼70  115 0.58 ∼85 165 0.15 ∼75 176 <0.01
∼37  109 0.66 ∼80 114 0.66 ∼65 133 0.34
∼25  87 0.65 ∼75 130 0.37 ∼45 149 0.14
∼62  156 0.16 ∼40 169 0.01
∼55  157 0.09
∼49  122 0.30
∼15  77 0.44
Cortex
Full lane 83 0.08 Full lane 89 0.48 Full lane 105 0.82
∼100  86 0.63 ∼150 60 <0.05 ∼130 153 0.16
∼75  62 0.35 ∼130 62 <0.05 ∼100 104 0.84
∼60  107 0.84 ∼100 96 0.84 ∼75 115 0.53
∼40  80 0.36 ∼70 94 0.68 ∼35 153 0.28
∼35  124 0.40 ∼49 91 0.27 ∼25 100 1.00
∼30  63 0.25 ∼37 76 0.07
∼27  85 0.59 ∼25 81 0.26
∼15  130 0.28
Cerebellum
Full lane 103 0.95 Full lane 93 0.95 Full lane 94 0.74
∼100  218 0.08 ∼70 112 0.72 ∼130 104 0.74
∼75  126 0.69 ∼69 112 0.65 ∼100 86 0.52
∼60  208 0.18 ∼50 111 0.72 ∼85 83 0.53
∼50  105 0.92 ∼40 88 0.79 ∼80 89 0.66
∼30  111 0.72 ∼35 129 0.70 ∼70 90 0.61
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troteolytically cleaves APP to produce A, increased levels of
hich, in turn, lead to amyloid plaque accumulation in this mouse
odel (for reviews see [12]).
Levels of protein SUMOylation and ubiquitination in Tg2576
ice: To determine if Tg2576 mice show modiﬁed SUMOyla-
ion and/or ubiquitination of substrate proteins, immunodetection
sing antibodies against SUMO-1, SUMO-2/3 and ubiquitin was
erformed in blots containing samples from Tg2576 and age-
atched wild-type mice. The global levels and individual bands of
osttranslationally modiﬁed proteins were analysed for hippocam-
us (Fig. 2A), cortex (Fig. 2B) and cerebellum (Fig. 2C).
Since global levels of SUMOylated proteins have been reported
o be increased in a number of neurodegenerative diseases (for
eview see [4])  and key proteins in AD have been implicated as
UMO substrates or SUMO-interacting proteins [9,10,20,33], we
ypothesised that altered levels of SUMO-conjugated substrates
ight be evident in Tg2576 mice. Conjugation by both SUMO-1
nd SUMO-2/3 displayed similar global levels in both transgenic
nd age-matched wild-type mice in all of the brain regions anal-
sed (Fig. 2A–C, left and centre panels). Similarly, the, global levels
f ubiquitin conjugates in the cortex and cerebellar regions were
nalogous between transgenic and age-matched wild-type mice
Fig. 2B and C, right panels). In contrast, however, global levels of
biquitin-conjugated proteins in the hippocampus of Tg2576 mice
ere signiﬁcantly increased compared to age-matched wild-type
ice (Fig. 2A, right panel).
Analysis of a selection of prominent bands revealed signiﬁcant
r very close to signiﬁcant changes in SUMO-1, SUMO-2/3 and
biquitin conjugation levels of individual proteins (Table 1). In
he hippocampus of Tg2576 mice, although increases in individual∼60  83 0.38
∼35 79 0.45
∼30  84 0.61
bands for SUMO-1 and SUMO-2/3 were apparent, these changes did
not reach signiﬁcance. Individual bands for SUMO-1 and SUMO-
2/3 in the cortex show apparent decreases: most strikingly, two
high molecular weight SUMO-2/3 conjugates at ∼130 and ∼150 kDa
showed a signiﬁcant decrease (Supplementary Fig. 1A). In the cere-
bellum, distinct bands in the SUMO-1 blot showed increases which
were close to signiﬁcance at ∼100 kDa and ∼60 kDa, whereas no
other bands showed apparent alterations. In conjunction with the
global changes in ubiquitin conjugation, several individual ubiq-
uitin bands were signiﬁcantly increased in the hippocampus of
Tg2576 mice (Supplementary Fig. 1B). In contrast, no signiﬁcant
changes in ubiquitination were evident in the cortex and cerebel-
lum.
SUMO-speciﬁc conjugating and deconjugating enzymes protein
levels in Tg2576 mice: To further investigate alterations in protein
SUMOylation in this model, we analysed the protein levels of the
SUMO conjugating enzyme, UBC9, and the SUMO-speciﬁc isopep-
tidase, SENP-1. Neither enzyme was  signiﬁcantly altered between
the Tg2576 and age-matched wild-type mice (Fig. 3A–C).
AMPA receptor subunit, GluA1, and KA receptor subunits,
GluK2/3, protein levels in Tg2576 mice: Since synaptic dysfunction
and/or loss is highly implicated as an early event in the pathophys-
iology of AD [24], we investigated total levels of the AMPA and KA
receptor subunits, GluA1 and GluK2/3, respectively, in the Tg2576
mice using the same tissue samples monitored for ubiquitination
and SUMOylation. The total levels of GluA1 and GluK2/3 were not
altered in any of the brain regions analysed in Tg2576 compared to
age-matched wild-type mice (Fig. 4A–C).
Our results conﬁrm that APP protein levels are dramatically
increased in the hippocampus, cortex and cerebellum of Tg2576
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Fig. 3. SENP-1 and UBC9 protein levels in Tg2576 transgenic and age-matched wild-type mice. Representative SENP-1 (left panels) and UBC9 (right panels) immunoreactivities
and  their respectives -actin loading controls in hippocampus (A), cortex (B) and cerebellum (C) of wild-type and Tg2576 mice. The experimental protocol was  as described
in  Fig. 1. Cumulative SENP-1 and UBC9 results for each region showing quantiﬁed data from at least six animals of each group are presented as percentage of wild-type ± SEM.
No  signiﬁcant difference compared to wild-type, p > 0.05.
206 L.E. McMillan et al. / Neuroscience Letters 502 (2011) 201– 208
Fig. 4. GluA1 and GluK2/3 total protein levels in Tg2576 transgenic and age-matched wild-type mice. Representative GluA1 (left panels) and GluK2/3 (right panels) immunore-
activities and their respectives -actin loading controls in hippocampus (A), cortex (B) and cerebellum (C) of wild-type and Tg2576 mice. The experimental protocol was as
described in Fig. 1. Cumulative GluA1 and GluK2/3 results for each region showing quantiﬁed data from at least six animals of each group are presented as percentage of
wild-type ± SEM. No signiﬁcant difference compared to wild-type, p > 0.05.
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ice. Moreover, a signiﬁcant increase in the global levels of ubiq-
itinated proteins, as well as several distinct molecular weight
onjugates, was observed in the hippocampus of Tg2576 mice.
nterestingly, signiﬁcant decreases in distinct high molecular
eight SUMO-2/3 conjugates were seen in the cortex of Tg2576
ice. Although multiple SUMO-1 and SUMO-2/3 bands appear to be
ltered in brain regions investigated, no other signiﬁcant changes
ere detected. Levels of the SUMOylating, UBC9, and deSUMOy-
ating, SENP-1, enzymes were also unaltered in any of the Tg2576
ice brain regions analysed. Surprisingly, given the reported loss
f synaptic function [13,17], total levels of the excitatory AMPA and
ainate neurotransmitter receptors were unaffected in the Tg2576
ice at the age we investigated.
Under pathological conditions, including AD, ubiquitin
mmunoreactive inclusion bodies accumulate, proteasomal
ctivity is decreased and deubiquitinating enzymes that promote
he degradation of accumulated proteins are downregulated
7,19]. In the brains of Tg2576 mice, it has been reported that the
biquitin–proteasome activity decreases with age while the A
evels increase [23]. In agreement with that previous study, we
bserved a signiﬁcant increase in the global levels of ubiquitinated
roteins in the hippocampus of Tg2576 mice, but not in the cortex
r cerebellum. The proteins that are increasingly conjugated to
biquitin in the hippocampus of Tg2576 mice remain unknown
nd to identify these was beyond the scope of our study.
Several AD-associated proteins, including APP and tau, have
een reported as SUMO substrates [9,11,33]. APP can be cova-
ently modiﬁed by SUMO-1 and SUMO-2, with these modiﬁcations
esulting in decreased production of A [33]. In addition, SUMO-
/3 has been variously reported to either increase [10] or decrease
20] A production. Further, it has been reported that tau can be
oth SUMOylated and ubiquitinated, and that proteasome inhibi-
ion increased tau ubiquitination and decreased tau SUMOylation
9]. Intriguingly, a polymorphism in the non-coding region of
BC9 has been reported to predominate in AD patients, although
he functional relevance of this observation was not investigated
1].  Furthermore, overexpression of UBC9 led to decreases in A
ggregation levels, and a localisation of UBC9 in the endoplasmic
eticulum where cleavage of APP by -secretase is thought to occur,
uggesting a role of the SUMO machinery in the regulation of amy-
oidogenic processing of APP [33].
Changes in global levels of protein SUMOylation in the Tg2576
D model have not been investigated previously. However, recent
eports have suggested differentiated patterns of SUMO conju-
ation in acute cell stress, such as brain ischemia [8,31],  and
n diseases characterised by the aggregation of misfolded aber-
ant protein or polyglutamine-related pathologies (reviewed in
4,10,22]). We,  and others, have previously demonstrated that
UMOylation is rapidly, dramatically and long-lastingly increased
n diverse acute neurodegenerative models of cerebral ischemia
8,31].  Based on these published results, we anticipated that we
ould detect altered SUMOylation levels in Tg2576 mice, together
ith, or independent from, changes in SUMOylation-speciﬁc enzy-
atic machinery.
Levels of ubiquitination were robustly increased in the hip-
ocampus with signiﬁcant increases in global levels as well as for
ndividual bands. Thus, protein ubiquitination in the vulnerable
ippocampus is altered in the transgenic mice, which may  reﬂect
 dysfunction of the ubiquitin–proteasomal degradation system.
n the cortex, signiﬁcantly decreased levels of SUMO-2/3 conju-
ation were observed for distinct high molecular weight bands at
150 kDa and ∼130 kDa. This suggests that the SUMOylation level
f these proteins may  be affected and an important task will be
o identify these SUMO substrates to deﬁne their relevance to AD.
he signiﬁcant differences seen in ubiquitin and SUMO-2/3 conju-
ation in the hippocampal and cortical regions are intriguing, asLetters 502 (2011) 201– 208 207
these regions are particularly vulnerable in the pathophysiology of
AD and merit further investigation.
Total levels of the SUMO-speciﬁc conjugating enzyme, UBC9,
and the dual-acting deconjugating and SUMO-maturating enzyme,
SENP-1, are not altered between Tg2576 and age-matched wild-
type mice. However, it is important to stress that these observations
do not rule out changes in subcellular distribution or activity of
these enzymes. Levels of additional components of the SUMO path-
way were not explored, such as E3 ligases, which assist in substrate
speciﬁcity and conjugation, and other SENP isoforms, with distinct
cellular roles emerging [30].
The development of senile plaques in the brains of Tg2576
mice starts after 10 months of age, whereas the synaptic activ-
ity is reduced from 8 months [13]. So at the age we investigated
(9 months) synaptic transmission is impaired but plaques are not
yet evident. The mechanisms underlying synaptic function deﬁcits
in AD have yet to be fully explained but there is evidence to sug-
gest that soluble oligomeric A rather than plaques cause impaired
synaptic function [5].  Surface expression of AMPA receptors, in
particular the GluA1 subunit, is reduced in some transgenic APP
overexpression models [3,6], which may  result from changes to
AMPA receptor trafﬁcking pathways [16]. To our knowledge, lev-
els of KA receptors have not been assessed in AD models, although
the activity of these receptors is affected by A in vivo [26]. More-
over, we  reported that multiple SUMOylation targets are present
at synapses and that SUMOylation can regulate the function of KA
receptors [21]. The fact that we did not observe loss of either AMPA
or KA receptors might be due to small changes beyond detection
using immunoblotting and/or by the possibility that loss of function
of these receptors results from reduced surface expression due to
internalisation rather than degradation. An alternative possibility is
that the deﬁcit in synaptic transmission arises from reduced presy-
naptic release rather than changes in postsynaptic AMPA and/or KA
receptors.
Our results suggest that global posttranslational modiﬁcation of
hippocampal proteins by ubiquitin and altered SUMO-2/3 conjuga-
tion in the cortex may  play an important role in the mechanisms
underlying AD. Identiﬁcation of these ubiquitin and SUMO sub-
strates and elucidation of their functional roles and regulation by
ubiquitination and SUMOylation will undoubtedly lead to new and
important insights into the pathophysiology of AD.
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